Progressive subretinal fibrosis in a child following hemolytic uremic syndrome (vol 19, pg 77, 1999)

被引：0

|

作者：

Krott

机构：

来源：

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES | 1999年 / 19卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

引用

收藏

页码：259 / 260

页数：2

相关论文

共 49 条

[31] Remyelination occurs as extensively but more slowly in old rats compared to young rats following fliotoxin-induced CNS demyelination (vol 28, pg 77, 1999)
Shields, SA
Gilson, JM
Blakemore, W
Franklin, RJ
GLIA, 2000, 29 (01) : 102 - 102
[32] IDENTIFICATION OF A CLONE OF ESCHERICHIA-COLI O103-H2 AS POTENTIAL AGENT OF HEMOLYTIC-UREMIC SYNDROME IN FRANCE (VOL 31, PG 297, 1993)
MARIANIKURKDJIAN, P
DENAMUR, E
MILON, A
PICARD, B
CAVE, H
LAMBERTZECHOVSKY, N
LOIRAT, C
GOULLET, P
SANSONETTI, PJ
ELION, J
JOURNAL OF CLINICAL MICROBIOLOGY, 1994, 32 (03) : 860 - 860
[33] Strategies for Surveillance of Pediatric Hemolytic Uremic Syndrome: Foodborne Diseases Active Surveillance Network (FoodNet), 2000-2007 (vol 54, pg S424, 2012)
Ong, K. L.
Apostal, M.
Comstock, N.
CLINICAL INFECTIOUS DISEASES, 2013, 57 (05) : 779 - 779
[34] Anti-Factor H Autoantibodies in a Fifth Renal Transplant Recipient with Atypical Hemolytic and Uremic Syndrome. American Journal of Transplantation (vol 9, pg 1223, 2009)
Le Quintrec, M.
Zuber, J.
Noel, L. -H.
Thervet, E.
Fremeaux-Bacchi, V.
Niaudet, P.
Fridman, W. -H.
Legendre, C.
Dragon-Durey, M. -A.
AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 (11) : 2647 - 2647
[35] Cell pathways' stock fell following the FDA's decision to reject Prevetac for adenomatous polyposis coli (vol 19, pg 10, 1999)
Zimmermann, J
GENETIC ENGINEERING NEWS, 1999, 19 (11): : 20 - 20
[36] Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome (vol 142, pg 310, 2003)
Veyradier
JOURNAL OF PEDIATRICS, 2003, 142 (06): : 616 - 616
[37] Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32 (vol 14, pg 703, 2005)
Esparza-Gordillo, J
de Jorge, EG
Buil, A
Berges, LC
López-Trascasa, M
Sánchez-Corral, P
de Córdoba, SR
HUMAN MOLECULAR GENETICS, 2005, 14 (08) : 1107 - 1107
[38] The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment (vol 100, pg 225, 2021)
Ariceta, Gema
Dixon, Bradley P.
Kim, Seong Heon
Kapur, Gaurav
Mauch, Teri
Ortiz, Stephan
Vallee, Marc
Denker, Andrew E.
Kang, Hee Gyung
Greenbaum, Larry A.
KIDNEY INTERNATIONAL, 2023, 104 (01) : 205 - 205
[39] The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment (vol 97, pg 1287, 2020)
Rondeau, Eric
Scully, Marie
Ariceta, Gema
Barbour, Tom
Cataland, Spero
Heyne, Nils
Miyakawa, Yoshitaka
Ortiz, Stephan
Swenson, Eugene
Vallee, Marc
Yoon, Sung-Soo
Kavanagh, David
Haller, Hermann
KIDNEY INTERNATIONAL, 2020, 98 (06) : 1621 - 1621
[40] The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment (vol 97, pg 1287, 2020)
Rondeau, Eric
Scully, Marie
Ariceta, Gema
Barbour, Tom
Cataland, Spero
Heyne, Nils
Miyakawa, Yoshitaka
Ortiz, Stephan
Swenson, Eugene
Vallee, Marc
Yoon, Sung-Soo
Kavanagh, David
Haller, Hermann
KIDNEY INTERNATIONAL, 2021, 99 (05) : 1244 - 1244

← 1 2 3 4 5 →